The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Rheumatol Ther
; 10(1): 73-93, 2023 Feb.
Article
de En
| MEDLINE
| ID: mdl-36227530
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Type d'étude:
Observational_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Langue:
En
Journal:
Rheumatol Ther
Année:
2023
Type de document:
Article
Pays d'affiliation:
Allemagne
Pays de publication:
Royaume-Uni